InsidersTradesSigma
삼성바이오로직스 Stock: price and management transactions · South Korea · DART (FSS)
Follow the 삼성바이오로직스 stock price and the full directors' dealings record of the company, a listed equity based in South Korea. Shares trade on KR KR, under the supervision of DART (FSS). Operating in the Health Care sector, 삼성바이오로직스 has logged 119 reports. Market capitalisation: €68,880.9bn. The latest transaction was disclosed on 20 May 2026 (Purchase). Among the most active insiders: 이재선. All data is accessible without an account.
117
Insider Decl.
n/a
Thresholds
n/a
36 ops.
Buy Volume
n/a
7 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate 삼성바이오로직스 Strong Buy (bullish), based on 25 analysts. Average price target: ₩1,975,520.
12Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 9,017 of 28,065 companies
60.4
score / 100
Value37
Quality84
FCF yld1.1%
Earn yld2.6%
EV/EBITDA25.1x
ROE18%
Gross mgn55%
Net mgn39%
Debt/EBITDA0.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 20 May 2026
Declarations119 total
Other
Other(filed)
Other
Other(filed)
25 of 119 declarations
About 삼성바이오로직스
Samsung Biologics is a South Korean company specializing in the manufacturing of biopharmaceutical products. It is listed on the Korea Exchange, XKRX.